THANK YOU FOR SUBSCRIBING
Pharma Tech Outlook Weekly Brief
Be first to read the latest tech news, Industry Leader's Insights, and CIO interviews of medium and large enterprises exclusively from Pharma Tech Outlook
Anju Mathew, CEO & Co-Founder After testing the innovative system with a renowned community cancer center for 18 months, the dynamic duo figured that there was a 90 percent reduction in the administrative burden. Through an automated platform, they streamlined redundant tasks at the hospital’s tumor board and eliminated the need for board members to gather data from different sources. With the vision to provide every cancer patient with access to the best possible minds, therapies, and innovations in care—OncoLenscame up with the idea of delivering a software as a service (SaaS) platform that replaces the labor-intensive process of collecting, presenting, and reporting cases for CoC (Commission on Cancer) and NAPBC (National Accreditation Program for Breast Centers) accreditation.
The platform merges case-specific clinical decision support criteria—including applicable clinical trials—to support the tumor board’s efforts to care treatment. “Through this platform, we can provide data such as available clinical trials or the latest solutions in precision medicine that physicians can bring up for discussion with the patients,” says Anju.
Our mission is to ensure that care providers are knowledgeable of and have access to the best treatment options available for the cancer patient, even in the community setting
OncoLens adheres to the regulatory mandates by using a HIPAA-compliant server and establishing data encryption and security needs in place. They also have specific features built into the system that ensures robust security for the platform.
As the next step in its mission to help physicians take the best possible decision for a patient at the right time, OncoLensis working on enhancing its ability to bring clinical trials to different community cancer sites. To that end, the firm has partnered with a clinical trial partner that can deploy OncoLens’ clinical trials ability to the site within 14 days in case of a patient match. Anju adds that OncoLens will also aim at building their clinical decision support platform by integrating additional cancer content into their platform in the near future.
Company
OncoLens
Management
Anju Mathew, CEO & Co-Founder and Lijo Sampson, CMO & Co-Founder
Description
Reducing the administrative burden around conducting tumor boards and reporting for CoC and NAPBC accreditation
ATLANTA - OncoLens and SARC Strategic Partnership Drives Nationwide Initiative for Enhanced Sarcoma Patient Care Underscoring their commitment to revolutionizing cancer care, OncoLens and the Sarcoma Alliance for Research Through Collaboration (SARC) are joining forces to introduce a nationwide, virtual sarcoma tumor board, providing unprecedented access to expert-led care for this rare form of cancer
OncoLens and the Sarcoma Alliance for Research Through Collaboration (SARC) are thrilled to launch a nationwide virtual sarcoma tumor board program as part of a strategic partnership to enhance patient care. This initiative is particularly impactful for providers and patients facing limited resources while tackling sarcoma—a rare and complex form of cancer. The OncoLens Virtual Tumor Board platform will grant medical professionals across the country access to the invaluable insights of top sarcoma experts.
In the increasingly intricate landscape of cancer care, the collective knowledge of experienced clinicians is vital for making informed decisions about patient treatment. And in the case of sarcoma, the input of multiple expert clinicians is more critical than ever to ensure access and education for the physicians and surgeons treating patients on the front lines. This partnership empowers SARC with the OncoLens platform— a powerful tool that unites experts and facilitates robust virtual discussions on complex cases.
"We are excited about our partnership with OncoLens and the SARC Multi-Disciplinary Tumor Board," said Dr. Scott Okuno, SARC's chief medical officer and professor of oncology at Mayo Clinic, "as this allows all sarcoma providers, regardless of whether they are practicing in a small, geographically remote center or a major center, to get opinions on how to treat and manage all types of bone and soft tissue sarcoma from experts in the sarcoma field."
The SARC Multidisciplinary Tumor Board (SMTB) brings together sarcoma experts, complementing the reach of local or regional tumor boards and providing a specialized platform for rigorous discussion of sarcoma patient cases pre- or post-diagnosis, surgery, or relapse. The SMTB provides a uniquely focused forum for physicians and surgeons to present sarcoma patient cases for in-depth, evidence-based discussion of tumor diagnosis and for managing a diverse patient population.
"In 2023 SARC proudly celebrates our twentieth year facilitating and driving team science," said Steven Young, president and chief executive officer of SARC, "and this partnership with OncoLens helps us extend support to the broader clinical community."
Anju Mathew, co-founder and chief executive officer of OncoLens, emphasized the transformative potential of the partnership: "We envision a world where every cancer patient has access to the best minds, therapies, and innovations in care – in time to make a difference. Collaborating with SARC helps us actualize this vision, particularly for sarcoma, which represents nearly 20% of childhood cancers and 1% of adult cancers. We're excited about making expert-led care accessible nationwide."